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A role for the Plasmodium falciparum cyclic GMP (cGMP)-dependent protein kinase (PfPKG) in gameto-
genesis in the malaria parasite was elucidated previously. In the present study we examined the role of PfPKG
in the asexual blood-stage of the parasite life cycle, the stage that causes malaria pathology. A specific PKG
inhibitor (compound 1, a trisubstituted pyrrole) prevented the progression of P. falciparum schizonts through
to ring stages in erythrocyte invasion assays. Addition of compound 1 to ring-stage parasites allowed normal
development up to 30 h postinvasion, and segmented schizonts were able to form. However, synchronized
schizonts treated with compound 1 for >6 h became large and dysmorphic and were unable to rupture or
liberate merozoites. To conclusively demonstrate that the effect of compound 1 on schizogony was due to its
selective action on PfPKG, we utilized genetically manipulated P. falciparum parasites expressing a compound
1-insensitive PfPKG. The mutant parasites were able to complete schizogony in the presence of compound 1
but not in the presence of the broad-spectrum protein kinase inhibitor staurosporine. This shows that PfPKG
is the primary target of compound 1 during schizogony and provides direct evidence of a role for PfPKG in this
process. Discovery of essential roles for the P. falciparum PKG in both asexual and sexual development
demonstrates that cGMP signaling is a key regulator of both of these crucial life cycle phases and defines this
molecule as an exciting potential drug target for both therapeutic and transmission blocking action against
malaria.
Cyclic GMP (cGMP)-dependent protein kinases (PKGs) are
the major intracellular mediators of cGMP signal transduction
in eukaryotic cells. Mammalian PKGs regulate a number of
physiological processes including smooth muscle relaxation,
platelet aggregation, intestinal secretion and hippocampal and
cerebellar learning (reviewed in reference 27). Unlike cAMP-
dependent protein kinase (PKA), PKG comprises both a cat-
alytic domain and a regulatory domain in a single polypeptide.
In the inactivated state, part of the regulatory domain (a sub-
strate-like sequence known as the autoinhibitory domain) is
thought to be bound to the catalytic domain. This binding is
released and the enzyme activated upon binding of cGMP to
the regulatory domain and opening of the substrate-binding
region within the catalytic domain (1, 14). The PKG of the
malaria parasite Plasmodium falciparum (PfPKG) and ortho-
logues from the related coccidian parasites Toxoplasma and
Eimeria are encoded by a single-copy gene and have been
shown to differ from the mammalian enzymes in several re-
spects. These include a larger number of cGMP binding sites
(three functional plus one degenerate) in the regulatory do-
main of the apicomplexan enzymes (6, 7, 17), highly coopera-
tive stimulation by cGMP (8, 17), and relative insensitivity to
8-substituted cGMP analogues (6, 7, 26). The parasite isoforms
also lack an N-terminal leucine zipper motif that mediates
homodimerization in mammalian isoforms, and evidence sug-
gests that they are monomeric (17). Interestingly, it has been
shown that the coccidian PKGs exist as both cytosolic and
membrane-associated (mediated by N-terminal myristoylation
and palmitoylation) isoforms (12), but the amino acid motifs
required for these modifications are absent in the PfPKG se-
quence, and it seems to lack acylated forms (8).
The coccidian PKGs have been shown to be the target of a
potent anticoccidial agent, 4-[2-(4-fluorphenyl)-5-(1-methylpi-
peridine-4-yl)-1H pyrrol-3-yl]pyridine (compound 1), which is
a competitive inhibitor of ATP binding (17). The selectivity of
the compound for apicomplexan enzymes is attributed to the
relative accessibility of a hydrophobic pocket that overlaps with
the ATP binding site conferred by a critical threonine residue
in the key “gatekeeper” position (T761 in Toxoplasma gondii;
T770 in Eimeria tenella) (11). Access is thought to be prevented
by the relatively bulky side chain of the residue that occupies
the corresponding position in mammalian PKGs. Expression
of compound 1-insensitive coccidian PKGs (harboring T/Q or
T/M gatekeeper residue substitutions) in Toxoplasma abol-
ished the effects of the inhibitor on the parasite, thus estab-
lishing that PKG is the primary target of compound 1 in T.
gondii. These compound 1-insensitive mutants were used to
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determine a role for coccidian PKG in secretion of micronemal
adhesive proteins, attachment to and invasion of host cells
and gliding motility of E. tenella sporozoites and T. gondii
tachyzoites. Compound 1 has also been shown to be a potent
inhibitor of the native P. falciparum PKG enzyme (50% inhib-
itory concentration [IC50] of 8.53 nM on cGMP-dependent
kinase activity in purified fractions using a fixed ATP concen-
tration of 5 M in the assay) but has limited in vivo activity in
the rodent malaria model P. berghei (8).
P. falciparum causes the most serious form of malaria in
humans and is responsible for the deaths of approximately one
million people each year. The parasite life cycle is complex
consisting of distinct phases in the mosquito vector and the
human host. Pathogenesis is caused by asexual parasites which
proliferate within red blood cells. The invasive form (merozo-
ite) enters a red blood cell and forms a ring-stage parasite. This
develops into a trophozoite which feeds on hemoglobin, and
the resulting schizont releases up to 32 daughter merozoites in
a 48-h cycle. A small proportion of the schizonts release mero-
zoites that differentiate into male or female gamete precursors
(gametocytes). These sexual cells are essential for malaria
transmission and must be taken up by an Anopheles mosquito
to continue the life cycle. Upon entering the insect midgut,
environmental cues trigger gametogenesis. Recently, we re-
ported that PfPKG plays an essential role in initiating this
process. The initial morphological change after activation of P.
falciparum gametocytes, from crescent-shaped to spherical
(known as rounding up), is inhibited by compound 1. Geneti-
cally manipulated parasites expressing a mutant (T618Q gate-
keeper substitution) compound 1-insensitive but fully active
PKG, introduced by allelic replacement, were resistant to the
effects of compound 1 on gametogenesis, demonstrating a di-
rect role for the enzyme in the initiation of this process (23).
There is also evidence suggesting a role for PKG in P.
falciparum erythrocytic stages. It has been reported that
PfPKG is expressed at both the mRNA and the protein level in
asexual blood stages, as well as the sexual phase of the life cycle
(6, 8). Although the PfPKG gene could be targeted for allelic
replacement, we were unable to disrupt it, suggesting an es-
sential role for PKG in P. falciparum asexual blood stage de-
velopment since it is this life cycle stage on which transfection
and drug selection of genetically modified parasites are per-
formed. Furthermore, we and others (8, 23) have observed that
compound 1 inhibits in vitro-cultured P. falciparum (IC50s in
the sub-low-M range depending on the isolate). Although the
role of PKG in the initiation of gametogenesis has been elu-
cidated, its role in erythrocytic stages was unknown prior to the
present study.
We demonstrate here that PfPKG has a central role in the
late stages of erythrocytic schizogony. Compound 1-treated P.
falciparum parasites develop normally through the trophozoite
stage but arrest late in schizont development, forming large
dysmorphic schizonts. Genetically manipulated P. falciparum
parasites expressing a compound 1-insensitive PfPKG are re-
sistant to the effects of both compound 1 and (a second imi-
dazopyridine PKG inhibitor) compound 2 on schizogony but
not to the broad-specificity serine/threonine kinase inhibitor
staurosporine. This demonstrates that PfPKG is the primary
target of the inhibitors and provides direct evidence that this
enzyme is essential for progression of the asexual erythrocytic
stage of the malaria parasite life cycle.
MATERIALS AND METHODS
Inhibitors. 4-[2-(4-Fluorphenyl)-5-(1-methylpiperidine-4-yl)-1H pyrrol-3-yl]
pyridine (compound 1) and 4-[7-[(dimethylamino)methyl]-2-(4-fluorphenyl)imid-
azo[1,2-a]pyridin-3-yl]pyrimidin-2-amine (compound 2) were gifts from Merck &
Co., Inc. Compound 1 and staurosporine (Sigma) were diluted to 10 mM in
dimethyl sulfoxide (DMSO; Sigma) and further diluted in RPMI 1640/albumax
(Invitrogen) to working dilutions.
P. falciparum cultivation. P. falciparum (clone 3D7) was grown in vitro using
human O erythrocytes in RPMI 1640–0.5% Albumax as previously described
(2). Synchronization was carried out by treatment with sorbitol according to
standard procedures (21). Mutant parasites (PfPKGT618Q harboring a human
DHFR [methotrexate resistance] allele) were maintained under selection with 5
nM WR99210 (an antifolate) and were generated as described previously (23).
Erythrocyte invasion assays and statistical analysis. For erythrocyte invasion
assays, schizonts were produced by magnetic purification and cultured in 96-well
plates at 1 to 2% parasitemia and 2% hematocrit as previously described (28).
Inhibitors (dissolved in 10% DMSO to give a final concentration of 0.5%) were
added to schizonts (wild-type 3D7 or PfPKGT618Q mutants derived from 3D7) at
a starting parasitemia of 0.5% and 1% hematocrit in 24-well plates in a humid-
ified chamber supplied with 7% CO2–7% O2 in N2. The proportion of ring-stage
parasitized red blood cells (rPRBCs) was measured by counting Giemsa-stained
thin blood films after approximately 24 h of treatment.
Samples were counted blind in triplicate (minimum 2,000 cells per slide) or in
replicates of six (1,000 per slide) and analyzed as proportions. Invasion assay data
were analyzed in SPSS using nested logistic regression analysis with a generalized
linear model (the factors included treatment and sample [treatment]). Nested
analysis was performed to detect variations in between treatments above the
variation between the replicates for an individual treatment. The data are pre-
sented as the exponential of the B statistic, with the 95% confidence interval (CI)
for Exp(B). The results are considered significantly different from the reference
group if the 95% CI for Exp(B) does not include 1. Graphs show proportions of
ring-infected parasitized erythrocytes. Error bars represent the mean binomial
error of the counts of replicate samples. The protocol used for treating parasites
for different periods of time is shown in Fig. S1 in the supplemental material.
IFA and Western blotting. For immunofluorescence assay (IFA) with the
Pf225 antibody, compound 1-treated (2 M) and untreated schizonts were
smeared and fixed with 1% paraformaldehyde as previously described (28). For
localization of Pf225 (PfRon4), the monoclonal antibody 24C6 4F12 (25), kindly
provided by Jean Francois Dubremetz, was diluted 1:100 and visualized with a
fluorescein isothiocyanate-labeled anti-mouse IgG antibody (Sigma). Nuclei
were stained with 0.5 g of DAPI (4,6-diamidino-2-phenylindole)/ml. Micros-
copy was performed by using a Deltavision cooled charged-coupled device im-
aging system. Images from the fluorescence microscope were collected and
deconvolved in Softworx and prepared in Adobe Photoshop with no further
manipulation. For IFA with the PKG and MSP1 antibodies, parasites were fixed
for 20 min with 4% paraformaldehyde, samples were permeabilized in 0.1%
Triton X-100 for 10 min and blocked overnight in 3% (wt/vol) bovine serum
albumin. Fixed samples were incubated with primary antibody (1:100), followed
by incubation with Alexa Fluor-coupled anti-rabbit or anti-mouse antibody (1:
5,000), respectively. Nuclei were stained with 0.5 g of DAPI/ml. Anti-human
PKGI antibody (PK10; Calbiochem) was raised in rabbit to a C-terminal pep-
tide (amino acids 657 to 671) and cross-reacts with PfPKG due to a high degree
of identity in this region, as previously noted (8, 23). Western blotting was
performed as previously described (23).
Electron microscopy (EM). For morphology, cells were fixed in 2.5% (vol/vol)
glutaraldehyde–0.75% (wt/vol) tannic acid in 0.1 M sodium cacodylate buffer
(pH 7.0) for 3 h at 4°C. They were osmicated (1% in cacodylate buffer), followed
by uranyl acetate (1%) staining, both for 1 h at 4°C, and then dehydrated in an
acetone series before being embedded in agar resin (Agar Scientific, Ltd., United
Kingdom). Epoxy resin sections were stained with uranyl acetate and lead citrate
and then examined in JEOL 1200EX and Hitachi 7600 electron microscopes.
RESULTS
Compound 1 prevents the progression of schizonts through
to rings but does not interfere with host cell kinases required
for invasion. The effect of compound 1 on asexual blood stage
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development was firstly investigated using a simple invasion
assay. This involved adding the inhibitor to purified, synchro-
nized P. falciparum schizonts and then measuring parasitemia
on Giemsa-stained blood films after 24 h of treatment. Schi-
zonts treated with either compound 1, staurosporine, or a DMSO
control (at 0.1, 1, or 5 M) showed that compound 1 (at 1 and
5 M) and staurosporine (at 5 M) inhibited progression from
schizonts to ring stages significantly (Fig. 1A [see the figure
legend for statistical analysis]). This could be due to an effect
on one or more events occurring between schizont develop-
ment and invasion. However, the persistence of schizonts in
the treated wells suggested that both compounds have some
effect on schizogony.
As an initial step to examine the specificity of compound 1
on P. falciparum asexual blood-stage development, uninfected
erythrocytes were pretreated with 10 M compound 1 or stau-
rosporine (for 1.5 h), followed by removal of the inhibitor by
washing before the addition of schizonts. This led to a signif-
icant reduction in parasitemia for staurosporine compared to
DMSO-treated control cells [Exp(B)  0.032; 95% CI  0.013
to 0.077] but not for compound 1 [Exp(B)  0.878; 95% CI 
0.694 to 1.110] (Fig. 1B). Merozoites could not invade eryth-
rocytes pretreated with staurosporine but could invade those
pretreated with compound 1. One possible interpretation is
that the effects of compound 1 are likely to be specific to a
parasite kinase, whereas the effects of staurosporine are likely
to be mediated in part against host cell kinases.
The effects of compound 1 on schizonts are reversible after
periods of treatment of <6 h. The results presented described
above (Fig. 1A) suggested that both compounds have an in-
hibitory effect on P. falciparum schizogony. We therefore ex-
amined the effects on schizogony of treatment with 2 M
compound 1 or 2 M staurosporine for increasing lengths of
time (1, 2, 3, 6, 12, and 24 h). Starting schizonts were between
38 and 42 h postinvasion. After treatment, the parasites were
washed and returned to culture and were observed again after
24 and 72 h (see Fig. S1 in the supplemental material for
experimental strategy). Giemsa-stained smears were prepared
from all cultures immediately after treatment. Figure 2 shows
a summary of the cell counts taken from these smears and
indicates that schizonts persist in both compound 1- and stau-
rosporine-treated cultures. A very low level of ring-stage par-
FIG. 1. Compound 1 inhibits progression of P. falciparum schizonts
to ring stages in erythrocyte invasion assays. (A) Proportion of rPRbCs
after 24 h treatment of schizonts with inhibitor or control. Bars rep-
resent the mean proportion of triplicate samples. Error bars represent
the mean binomial error of the proportions. The data were further
analyzed in SPSS by using nested logistic regression analysis with a
generalized linear model (factors included treatment and sample
[treatment]). Counts were performed in triplicate or replicates of six.
Control versus compound 1: 1 M, Exp(B)  0.125; 95% CI  0.039
to 0.397. Control versus compound 1: 5 M, Exp(B)  0.206; 95%
CI  0.113 to 0.376. Control versus staurosporine: 5 M, Exp(B) 
0.234; 95% CI  0.130 to 0.421. The results marked with asterisks (**)
showed a statistically significant difference in rPRBCs from the DMSO
control group [the 95% CI for Exp(B) did not include 1]. (B) Propor-
tion of ring stage-parasitized RBCs 24 h after the start of the experi-
ment using erythrocytes that had been treated (for 1.5 h) with inhibitor
or control. Bars represent the mean proportion of triplicate samples.
Error bars represent the mean binomial error of the proportions. The
data were further analyzed in SPSS as described above.
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FIG. 2. Schizonts persist and do not lead to normal levels of ring-stage
parasite formation after inhibitor treatment for 1 to 24 h. Starting schi-
zonts (38 to 42 h postinvasion) were treated with inhibitor or control for
increasing lengths of time. Immediately after treatment, the parasites
were smeared, and parasitemia measured after Giemsa staining. This
figure shows the counts taken from these smears. (A) Bars represent the
percentage of schizonts remaining in cultures treated with inhibitor or
control for periods of time between 1 and 24 h. (B) Bars represent the
percentage of resulting ring-stage parasites in cultures treated with inhib-
itor or control for periods of time between 1 and 24 h.
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asites was observed at each treatment length, showing that the
majority of schizonts could not release invasive merozoites.
Control treatment of schizonts with DMSO shows the expected
gradual decrease in schizonts (Fig. 2A) and consequent in-
crease in rings (Fig. 2B) over time after successful schizont
rupture and red cell invasion.
The proportion of rPRBCs for all treatment lengths was
measured 24 h after starting treatment (see Fig. S2A in the
supplemental material). A significant reduction in rPRBCs was
seen in cultures treated with staurosporine for 1 h or more,
showing that schizonts could not recover from even a short
period of treatment with staurosporine (see Fig. S2A in the
supplemental material). In contrast, treatment with compound
1 is reversible to some extent. Although parasites treated with
compound 1 were developmentally delayed for a period cor-
responding to the length of the treatment time, they were able
to recover fully if treatment was for 1 or 2 h. Analysis of the
data for parasites treated for 3 h suggests a very slight reduc-
tion in the proportion of rPRBCs if a nested model taking into
account the variation between the replicate samples is used
[Exp(B)  0.761; 95% CI  0.590 to 0.981)], but if a simpler
model is used that only compares the treatment this result is
not significant [Exp(B)  0.761; 95% CI  0.908 to 1.113].
More obvious differences occur after 6 h treatment, where the
proportion of rPRBCs at 24 h drops significantly [nested model:
Exp(B)  0.619; 95% CI  0.477 to 0.802] and more so after
12 h and 24 h (see Fig. S2A in the supplemental material).
Parasitemia was checked 24 h after starting (see Fig. S2A in
the supplemental material) and again after 72 h (see Fig. S2B
in the supplemental material). For the 72-h measurements,
cultures were diluted 1/10 at 24 h to ensure parasitemia levels
did not rise too high in the second cycle (see Fig. S1 in the
supplemental material). Parasites treated with compound 1 for
up to 6 h showed the same level of parasitemia as the control
treated cultures after 24 and 72 h (with a difference in age
corresponding to the developmental delay). However, after
12 h of treatment, the parasitemia levels at 24 h were 3-fold
lower than those of the control (3.1% rings compared to 10%)
and, after 24 h of treatment, the mean percentage of the rings
was 0.36% compared to 9.69% in the control. After 72 h, the
mean percentage of the rings had fallen further to 0.14%,
indicating that although compound 1 is a reversible inhibitor,
irreversible damage to the schizont occurs after prolonged
treatment (see Fig. S2 in the supplemental material).
Schizonts treated with compound 1 for prolonged periods
show aberrant morphology. Development was slowed in the
compound 1-treated schizonts and distinct morphological ab-
normalities visible by light microscopy were apparent after
between 6 and 12 h of treatment (compared to 3 h for stauro-
sporine) and more strikingly obvious after 24 h of treatment.
Compound 1-treated schizonts stained less well with Giemsa,
and the intracellular merozoites looked more separated and
irregularly spaced than in untreated schizonts (Fig. 3A). To
study these morphological abnormalities in more detail, we
took purified schizonts and treated them with 2 M compound
1 for 24 h for IFA and EM analysis. Localization of the rhoptry
neck protein Pf225 (PfRON4) and MSP1 were apparently nor-
mal in the inhibitor-treated parasites (Fig. 3B and C), as were
those of the microneme proteins AMA1 and EBA175, the
apical protein RH2b and the calcium-dependent protein ki-
nase CDPK1 (data not shown). A polyclonal PKG anti-peptide
antibody that reacts with an 100 kDa band on Western blots
of mixed stage P. falciparum proteins (denatured and nonde-
natured, Fig. 3D) was also tested on compound 1-treated schi-
zonts (Fig. 3C, lower panels). The staining pattern observed
throughout the merozoites suggests a predominantly cytosolic
localization. The pattern was similar in both treated and un-
treated schizonts and was not observed in earlier asexual
blood-stage parasites.
Schizonts treated with 2 M compound 1 for 24 h were also
examined by transmission EM. Consistent with the light mi-
croscopy results, aberrant morphology was clearly observed
when the ultrastructure of schizont stages, treated with a 24-h
exposure of compound 1 (Fig. 4B and C), is compared to
untreated controls (Fig. 4A). Under these conditions schizont
development was arrested, with the majority being unable to
reach the point where they can rupture. The population of
treated schizonts comprised parasites with 8 to 16 nuclei
stages, segmented schizonts that are still attached to the resid-
ual body, as well as fully segmented schizonts. Thus, compound
1 did not appear to synchronize development to an obvious
morphological/time point. In treated schizonts (Fig. 4B and C)
merozoite morphology is abnormal, with many of the major
organelles ill defined or “leached out,” there is an increase in
the amount of membranous material, as well as evidence of
membrane fragmentation (notably the parasitophorous vacu-
olar membrane [PVM] and possibly the parasite plasma mem-
brane [PM]). In some schizonts the red blood cell cytosol
appears to be partially digested (loss of dense staining and a
mottled appearance, Fig. 4B and C); this would be consistent
with PVM/PM perforation and the leakage of proteases into
the red blood cell.
PfPKG is central to schizogony. To establish whether the
effect of compound 1 on P. falciparum schizont development
was due to the action of the inhibitor on PfPKG or on an
alternative target, we used genetically manipulated P. falcipa-
rum parasites expressing a compound 1-insensitive PfPKG in-
troduced into the haploid parasite genome by allelic replace-
ment. This mutant line is also insensitive to a distinct
anticoccidian PKG inhibitor (4-[7-[(dimethylamino)methyl]-2-
(4-fluorphenyl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine,
compound 2). Compound 2 has been shown to have very sim-
ilar actions to compound 1, but additional parasite protein
kinase targets (casein kinase 1 and calcium-dependent protein
kinase 1) have been identified in T. gondii (13). The inhibitor-
insensitive P. falciparum line expressing a mutant PfPKG en-
zyme (T618Q) was generated by allelic replacement. No dif-
ferences in the growth rates of either sexual or asexual parasites
were noted between mutant and wild-type parasites in the
absence of compound 1. These observations confirm that the
mutant kinase is fully active and that the genetic manipulation
procedure had had no detectable effects on parasite develop-
ment (23).
Treatment of purified wild-type schizonts with either 2 M
compound 1, 0.5 to 2 M compound 2, or 5 M staurosporine
dramatically reduced the formation of ring-stage parasites in
invasion assays (Fig. 5A). In contrast, schizogony was able to
proceed, and ring-stage parasites developed at normal levels
after treatment of PfPKGT618Q mutant schizonts with com-
pounds 1 and 2 at these concentrations (Fig. 5B and C). There
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was no difference between the parasitemia levels or develop-
mental stage of compound 1- or compound 2-treated versus
control DMSO-treated PfPKGT618Q parasites. Ring-stage par-
asite formation in staurosporine-treated mutant schizonts was
fully inhibited, as observed with wild-type parasites (Fig. 5B
and C). Wild-type schizonts treated with compound 1 or stau-
rosporine did not rupture and showed aberrant morphology
(Fig. 5C, left panels). In contrast, compound 1-treated schi-
zonts expressing PfPKGT618Q were able to rupture and to form
ring-stage parasites after reinvasion (Fig. 5C, upper right
panel). The presence of the mutant PKG did not reverse the
inhibitory effects of staurosporine on schizonts since it is likely
to target numerous protein kinases in Plasmodium. Together,
these data demonstrate conclusively that the effects of com-
pounds 1 and 2 on schizont development are due primarily to
the action of the inhibitors on PfPKG and provide direct evi-
dence for a key role for PKG in schizogony.
DISCUSSION
When a P. falciparum merozoite enters the human blood-
stream after release from a schizont, it must quickly bind to
and invade a red blood cell to escape the lethal environment.
In the present study, we have utilized highly specific inhibitors
FIG. 3. Treatment of schizonts with compound 1 causes morphological abnormalities, but merozoite proteins localize normally. (A) Giemsa-
stained smears of untreated or schizonts treated with 2 M compound 1 for 24 h. Scale bar, 5 m. (B) Fluorescence micrographs of untreated
schizonts or schizonts treated with 2 M compound 1. The primary antibody was a monoclonal antibody that reacts with the P. falciparum rhoptry
neck protein Pf225 (green). Nuclei were counterstained with 0.5 g/ml DAPI (blue). Scale bar, 5 m. (C) Fluorescence micrographs of schizonts
treated with 2 M compound 1. The primary antibodies were a monoclonal antibody that reacts with P. falciparum MSP1 (top row) and a
polyclonal antibody that reacts with PfPKG (bottom row) (both green). Nuclei were counterstained with 0.5 g/ml DAPI (blue). (D) Western blots
containing mixed-stage P. falciparum (clone 3D7) parasites separated on both native and denaturing polyacrylamide gels. The PKG antibody was
raised to the C-terminal peptide of human PKGI and cross-reacts with PfPKG due to the high degree of sequence identity at the C terminus.
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in conjunction with inhibitor-insensitive transgenic parasites to
demonstrate a central role for the parasite cGMP-dependent
protein kinase in regulating the progression of P. falciparum
schizogony.
This study was initiated based on previous evidence that
cGMP and PfPKG are involved in P. falciparum asexual rep-
lication, but it was not clear at which phase of the cycle PfPKG
may be involved or what its precise role might be. Previous
work using the potent nonselective protein kinase inhibitor
staurosporine suggested a role for protein kinases in invasion
of erythrocytes by Plasmodium (9, 29) and host cell invasion by
Toxoplasma (4). We therefore began by testing the PKG in-
hibitor compound 1 in erythrocyte invasion assays. Our results
showed that compound 1 is a more potent inhibitor of ring-
stage formation than staurosporine in these assays. The results
also show that, unlike staurosporine, compound 1 has no ad-
ditional effects on host red cell kinases, suggesting that its
inhibitory effects are specific to parasite molecules. The previ-
ous study which investigated the effects of staurosporine on P.
knowlesi merozoite invasion concluded that the inhibitor had
little or no effect on rhesus monkey red blood cells (29); the
different conclusion may be due in part to the shorter pretreat-
ment period used in the earlier study.
Inhibition of ring-stage formation by a test compound in an
invasion assay does not necessarily indicate direct interference
with the invasion process itself. We therefore looked more
closely at the treatment of schizonts with compound 1 and
staurosporine. The treatment of schizonts for increasing lengths
of time showed clearly that they were unable to rupture and
were irreversibly damaged after prolonged treatment. It was
possible to reverse these effects using shorter treatment peri-
ods (1 to 3 h), indicating that compound 1 is a reversible
inhibitor. This contrasted with staurosporine treatment, where
even short periods of treatment led to irreversible inhibition of
schizogony. This probably reflects the likelihood that stauro-
sporine, a broad-range ATP-competitive kinase inhibitor, has
numerous targets in the parasite.
Although schizonts treated with compound 1 for 6 to 24 h
exhibited aberrant morphology by Giemsa staining, immuno-
staining with antibodies raised to specific merozoite proteins
showed apparently normal localization, indicating limited dis-
ruption of schizont formation. It is possible that the appear-
ance of Giemsa-stained schizonts after compound 1 treatment
may be due to destabilizing effects on the PVM and PM that do
not adversely affect expression and trafficking of the merozoite
membrane proteins tested. The pattern obtained by EM anal-
ysis was consistent with Giemsa-staining of schizonts treated
with compound 1. There was clear evidence of membrane
disruption, but it is not clear whether or not these morpholog-
ical abnormalities are a primary effect of the inhibitor or sec-
ondary effects after arrest.
The arrest of schizogony prior to rupture by compound 1
suggests a potential role for PKG at this stage of the life cycle.
This idea is consistent with genome-wide microarray data that
measured peak expression of PfPKG mRNA levels in late
schizonts (22) (PlasmoDB [http://plasmodb.org]). Further-
more, IFA with the anti-PfPKG antibody suggests that the
protein is expressed in late trophozoites but peaks in schizonts.
However, earlier work reported peak expression of PfPKG and
native cGMP-dependent kinase activity in P. falciparum ring-
stage parasites and gametocytes (6, 8). The discrepancy in the
asexual stage specificity of activity might be partly explained
by the relative purity of parasite preparations between studies
or the possibility that native PfPKG present in schizont lysates
may already be fully activated and therefore not stimulated
further by cGMP addition in kinase assays. Genes respon-
sible for the synthesis (encoding guanylyl cyclase PfGC
[PF11_0395]) and hydrolysis (encoding phosphodiesterases
PfPDE [PFL0475w], a cGMP-PDE [30, 32], and PfPDE
[MAL13P1.118], a PDE with potential for dual substrate spec-
ificity [30]) of cGMP also have peak mRNA expression in late
schizonts (PlasmoDB). This further suggests a role for the
cGMP signaling pathway at this stage of parasite development.
It is clear that all protein kinase inhibitors have the potential
to target more than one enzyme in the cell, and it is necessary
to generate an inhibitor-insensitive line to demonstrate speci-
ficity. We previously reported that in a compound 1-insensitive
P. falciparum line (expressing a mutant PKG with its capacity
FIG. 4. EM morphology of untreated and compound 1-treated schizonts. (A) Untreated control P. falciparum segmented schizont. Scale bar,
1 m. (B and C) Electron micrographs showing schizonts after treatment with 2 M compound 1 for 24 h. Hz, haemozoin; rbcm, red blood cell
membrane; PVM, parasitophorous vacuolar membrane; PM, plasma membrane. Scale bar, 1 m.
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to bind to compound 1 reduced 3,000-fold), the effects of the
inhibitor on the initiation of gametogenesis were abolished and
thereby established specificity for PfPKG (23). In the present
study we showed that the effects of the PKG inhibitors com-
pound 1 and compound 2 on schizogony in this P. falciparum
line were abolished, demonstrating that PfPKG is the primary
target of these inhibitors during this process and highlighting
an essential role for this kinase in schizogony.
To determine whether the inhibitors affect P. falciparum
throughout the erythrocytic cycle or specifically schizont stages, a
tritiated hypoxanthine incorporation assay was performed on
synchronized ring stage parasites (starting treatment approxi-
mately 2 to 6 h after invasion). Interestingly, ring-stage para-
sites treated with either compound 1 or compound 2 (4 M)
showed a reduced level (ca. 25%) of incorporation of tritiated
hypoxanthine over the subsequent 56-h assay period compared
to DMSO-treated controls (data not shown). This suggests that
there is reduced nucleic acid synthesis in the presence of either
compound even though the morphology of trophozoites and
developing schizonts is normal. However, when this experi-
ment was repeated on both the wild type (clone 3D7) and the
inhibitor-insensitive line, the slight decrease in hypoxanthine
incorporation was seen in both parasite lines in the presence of
either compound 1 or compound 2 (data not shown). This
suggests that (in contrast to the effects on schizont rupture) the
effects of both compounds on hypoxanthine incorporation are
not (primarily) due to inhibition of PfPKG but rather are a
result of inhibition of other P. falciparum kinases as secondary
targets of compounds 1 and 2 during the period of DNA
synthesis. We previously reported a similar phenomenon during
sexual development, where the effects of the compounds on the
first step of gametogenesis were specific to inhibition of PKG, but
not the later events and that secondary targets were likely in-
volved during the subsequent steps of exflagellation (23).
Compound 1 and inhibitor-insensitive parasites were used
previously to elucidate a role for PKG in secretion of the
micronemal adhesive proteins (TgMIC2 and EtMIC1 and -2),
gliding motility, and attachment to and invasion of host cells of
E. tenella sporozoites and T. gondii tachyzoites (31). Interest-
ingly, staurosporine also inhibits release of the Toxoplasma
MIC2 (4) that mediates host cell attachment and invasion (3,
18). In Toxoplasma it is known that increases in intracellular
calcium can trigger microneme discharge (5). Inhibitor stud-
ies have implicated a calcium-dependent protein kinase
(TgCDPK1; not the orthologue of the Plasmodium CDPK1) in
TgMIC2 secretion, gliding motility, and host cell attachment
and invasion (10, 20). Evidence thus points to a role for both
PKG and a calcium-dependent kinase in these processes. Pur-
falcamine, an inhibitor of the calcium-dependent protein
kinase PfCDPK1, was also reported to cause the arrest of
P. falciparum schizont development. Microarray analysis has
shown that the PfCDPK1 mRNA clusters with other mRNAs
encoding a number of motor complex proteins associated with
parasite motility (which may indicate a shared function), and
the enzyme has been shown to phosphorylate one of these
(myosin A tail domain interacting protein [MTIP]). It was
concluded that PfCDPK1 could play a role in motor-depen-
dent parasite processes such as cytokinesis and merozoite
egress that occur in late schizonts (19). Independent confirma-
tion that PfCDPK1 can phosphorylate MTIP, as well as glid-
eosome-associated protein 45 (GAP45), has been obtained
(16). It was concluded that the localization of CDPK1 at the
periphery of the merozoite was consistent with its interaction
with motor complex proteins during erythrocyte invasion. In-
FIG. 5. Mutant schizonts expressing a compound 1-insensitive PfPKG
progress through to ring stage normally in the presence of compound 1 in
erythrocyte invasion assays. The proportions of ring parasitized RBCs in
wild-type (WT) (A) and compound 1-insensitive (PfPKGT618Q) (B) parasite
lines measured after treatment for 24 h with either compound 1, compound
2, staurosporine, or DMSO alone. Bars represent the mean proportion of
triplicate samples. Error bars represent the mean binomial error of the pro-
portions. The data were further analyzed in SPSS as for Fig. 1. The results
marked with asterisks (**) showed a statistically significant reduction in
rPRBCs from the DMSO control group [the 95% CI for Exp(B) did not
include 1]. (C) Giemsa-stained smears of compound 1 and staurosporine-
treated wild-type and PfPKGT618Q parasites. Scale bar, 5 m.
VOL. 9, 2010 MALARIAL cGMP-DEPENDENT PROTEIN KINASE 43
 o
n
 D
ecem
ber 1, 2011 by SW
ETS SUBSCRIPTIO
N SERVICE
http://ec.asm
.org/
D
ow
nloaded from
 
terestingly, phosphorylation of GAP45 controls the assembly
of the Toxoplasma myosin XIV motor complex (15). Use of a
potent inhibitor of CDPK1 (the bisindolocarbazole, K252a)
prevented merozoite egress (16), which is reminiscent of the
effects of PfPKG inhibition by compounds 1 and 2. Although
the specificity of these CDPK1 inhibitors requires confirma-
tion, the investigation of how calcium and cGMP signaling
might coregulate schizogony and parasite egress will be a di-
rection of future work.
In the present study we demonstrated that PfPKG has a
central role in P. falciparum schizogony and that it can be
targeted specifically in this life cycle stage by the trisubsubsti-
tuted pyrrole, compound 1, and the imidazopyridine, com-
pound 2—both of which are potent anticoccidial PKG inhibi-
tors. Previously, we demonstrated a crucial role for PfPKG in
the initiation of gametogenesis (23), and our recent data indi-
cate an additional role in ookinete motility (24). This estab-
lishes PfPKG as a potentially exciting drug target in the ma-
laria parasite for the following reasons. The anticoccidial
agents compounds 1 and 2 are able to inhibit P. falciparum
development, and their effects are both specific to PKG and
selective for the parasite isoform. However, it is clear from the
strategy used here that resistance to these particular com-
pounds can be conferred by substitution of a single residue and
also that the activity of these compounds against P. berghei in
vivo is limited (8). PfPKG is the first example of a validated P.
falciparum drug target whose inhibition could have both ther-
apeutic and transmission blocking effects.
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